# Intake-Readiness — Enterprise EHR Platform (rev 3 of readiness; intake pack rev 2)

Task: HEAAA-3. Source: `docs/intake/` at commit `6ea01b5` (intake pack revision 2, 2026-11-02 03:26 PKT). Prepared by Intake Agent 2026-11-04.

## Source and decision register
| ID | Source | Revision | Authority |
|---|---|---|---|
| S1 | docs/intake/01–06 | 6ea01b5 | Confirmed by Zain Naeem (product owner), 2026-10-31, updated 2026-11-02 |
| S2 | docs/intake/07-OPEN-QUESTIONS.md sections A, B, D, E | 6ea01b5 | Answered by Zain Naeem 2026-11-02 03:26 PKT (UTC+05:00), recorded by AI assistant |
| S3 | Earlier readiness score | rev 1 | 43.75%, superseded by this rescore |

Supersession: S2 answers supersede rev 1 assumptions (country, pharmacy model, EPCS, budget, date). No conflicting requirements found. Original recordings/transcripts of the Q&A session were not supplied; the record is the AI assistant's note, confirmed by the owner (limitation).

## Scores (1 / 0.5 / 0)
| Area | Score | Evidence |
|---|---|---|
| Goals | 1 | 01 §3 measurable targets, agreed |
| Users/permissions | 1 | 01 §4, 02 per-portal features |
| Journeys/rules | 1 | 03 workflows; lab release policy B4 |
| Scope/acceptance | 1 | 01 §5–6 in/out scope, R1–R4 agreed (B1) |
| Data/integrations | 0.5 | Standards defined; named labs/pharmacies (C3), existing systems (C1), cloud (C6), partner pharmacy count open |
| Traffic/reliability | 1 | D1/D2 volumes, D6 targets agreed |
| UX | 0.5 | WCAG target agreed; brand files, imagery, domains, languages open |
| Budget/timeline/owners | 1 | D3–D5, section E owners (single person) |

**Total: 7 / 8 = 87.5%.**

## Critical gaps
None block discovery. Section A critical questions are answered.

## Non-critical gaps and consequences
1. Operating states (A1): blocks telehealth licensing and state pharmacy rules analysis. Must be resolved before G1.
2. Budget risk: US$150k–300k for R1–R3 at this scale and EPCS scope, in 6 months, is flagged by the assistant as likely too low. Discovery must size R1; trimming is decided at G1.
3. No independent clinical safety reviewer; Zain Naeem holds all gate roles (allowed by SDLC, but patient-safety rules need licensed clinical review before go-live).
4. Open: named labs/pharmacies, cloud provider, AI features, languages, brand files, domains, 3-year growth.

## Decision request
Proposed: **START** scoped discovery (Researcher/BA/PM) on baseline S1+S2 at 87.5%, with these limits: assumptions for open items are not requirements; R1 assumes English, no migration; discovery must return operating states and the budget/scope fit analysis for G1. Alternatives: Update (answer more questions first), Provisional, Hold.

This document is not approval. Approval requires the human INTAKE decision on the confirmation attached to this task.
